Antiviral Drug Discovery To Address the COVID-19 Pandemic release_6rvunadsvjcmxbnv2ppio67jtu

by douglas richman

Published in mBio by American Society for Microbiology.

2020   Volume 11

Abstract

<jats:title>ABSTRACT</jats:title> The magnitude of the morbidity and mortality inflicted upon the global population in less than 1 year has driven the inescapable conclusion that the discovery and development of effective antiviral drugs for COVID-19 are urgent and should be prioritized. The antiviral drug discovery programs that emerged for HIV and hepatitis C virus have enabled technology and expertise to accelerate this process for SARS-CoV-2. The description of candidate lead inhibitors for the viral main protease (M<jats:sup>pro</jats:sup>) exemplifies this accelerated approach and reminds us of the needs and opportunities for addressing this pandemic.
In application/xml+jats format

Archived Files and Locations

application/pdf  203.2 kB
file_62i5nytiwfd6fbi4z2f4xhvhna
web.archive.org (webarchive)
mbio.asm.org (publisher)
Read Archived PDF
Archived
Type  article-journal
Stage   published
Date   2020-09-25
Language   en ?
Container Metadata
Open Access Publication
In DOAJ
In ISSN ROAD
In Keepers Registery
ISSN-L:  2150-7511
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 18ca6b1f-a33a-4660-a2e3-707074d1a8a8
API URL: JSON